Recursion Pharmaceuticals, Inc. (RXRX) shares gained 12.32 percent to $3.9650, up $0.4350 on Wednesday, after the company reported a sharp increase in fourth-quarter revenue and a narrower quarterly net loss.
The stock is currently trading at $3.9650, compared with a previous close of $3.5300. It opened at $3.9100 and has traded between $3.8100 and $4.0800 during the session. Trading volume stands at 23.80 million shares, slightly above its average volume of 21.78 million shares.
For the fourth quarter ended December 31, 2025, total revenue rose to $35.5 million from $4.5 million a year earlier, driven primarily by a $30 million milestone payment under its collaboration with Roche and Genentech, as well as higher activity with Sanofi. Net loss narrowed to $108.1 million from $178.9 million.
The stock has traded in a 52-week range of $2.9800 to $9.7400.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.